Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Eledon Pharmaceuticals' stock, predicting its value could rise significantly.
Financial Health
Eledon Pharmaceuticals is showing solid cash flow and a favorable book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ELDN
Penny Stocks to Watch
Looking for the next big thing at a small price? This carefully selected group of stocks under $5 has caught the attention of professional hedge funds. These hidden gems might offer significant growth potential for investors willing to take on some risk.
Published: May 27, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical milestones ahead
Trial results and regulatory updates can materially move the stock, presenting opportunities — though outcomes are binary and timelines can be long.
Niche therapeutic focus
Targeted programmes may address unmet needs and attract partners, but niche indications can limit near‑term revenue potential.
Funding and dilution
Small‑cap biotechs often raise capital via equity or deals; watch the cash runway carefully, as financing can dilute existing shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
